Emerging markets are typically met with outright skepticism before transitioning into mainstream acceptance, and in many instances, the initial skepticism is healthy. Overcoming that skepticism, however, requires a convincing dose of proof and hard work to convert misconceptions into knowledge on a subject.
Today, several high-profile and rising markets are excellent examples of such a quandary, from CBD products to cryptocurrencies — public perception needs molding with valid information and arguments.
In the case of nootropics, a class of substances known as cognitive enhancers, combatting public misconceptions takes clinical research, trials, and exploration by medical institutions. Anecdotal evidence has largely been the primary avenue of nootropic discussions, limited to circles of athletes, former drug addicts, curious parties facing mental challenges, and more — all touting the cognitive advantages of the class of substances.
“In accordance with these science-backed initiatives, we want individuals from all spectrums of society to use nootropic supplements,” says Sammy Tran, Chief Marketing Officer of Nuoptimal. “To achieve this, we’re focusing heavily on education to ensure our customers know exactly what they’re taking and the benefits behind each ingredient.”
Interestingly, many of the most well-known nootropics are commonly found in everything from green tea to plants like Ginkgo Biloba. The traditional obstacle in exploring the benefits of nootropics was the lack of formal clinical pathways, but that is all changing.
Clinically Backed Results
Neuroscientists, dieticians, and mental health professionals are pushing further research into the cognitive enhancement capabilities of nootropics, which have undergone a slew of trials and academic studies in recent years.
For example, the nootropic Acetyl L-Carnitine has been vigorously examined as a neuroprotective agent against inborn metabolic imbalances that are relevant in Alzheimer’s, traumatic brain injuries, and peripheral nervous system injuries. Such research is vital to producing the type of evidence that the medical community, regulators, and the broader public needs to overcome initial skepticism on a new product or market — like a class of cognitive enhancers.
However, the journey to unmasking the benefits of nootropics is sometimes more personal, derived from traumatic experiences and years of ambition to improve oneself.
For Mau Pan, the CEO of Nuoptimal, his life journey is what led him down the nootropics rabbit hole — as part of a confluence of initiatives to improve his life following a series of tragedies and eventual realizations. Through Nuoptimal, Pan and his team are driving the broader conversation around nootropics, starting with their flagship product metaBRAIN, a comprehensively formulated box of three nootropic supplements.
“We’re working on a quantitative study with Cambridge Brain Sciences to bolster the understanding and efficacy of nootropics use in high-impact areas,” says Timothy Peou, Nuoptimal’s Chief Strategy Officer. “We’ve seen individuals of all lifestyles benefit from nootropics from their work performance to their everyday lives.”
Nuoptimal is among a subset of entities spearheading research and production of scientifically-backed nootropic supplements for the public. Following their extensive research on these compounds, Nuoptimal is rectifying many of the misconceptions individuals might have about nootropics.
Often, misconceptions about products are born from a hesitancy towards change and whether or not a product comes from sound investigation and composition. In the case of supplements, the optimal method for validating their authenticity is through medical pathways, a situation similarly ongoing with CBD and something not lost on Nuoptimal.
“Each market has a unique avenue for proving the sustainability and viability of a product,” says Pan. “The clinical acceptance of nootropics have come a long way and with our science-backed approach, we aim to quantify the cognitive improvements nootropic supplements may provide.”
Nuoptimal’s study with Cambridge Brain Sciences on their flagship brain supplement reflects the importance of measuring the efficacy of nootropics — the type of spark that is necessary to overcome public misconceptions about this emerging market.
Clinical evidence is obviously not the broad stroke solution for products in tech or construction but instead reflects the independent trajectory that a firm must take to prove the staying power of their product — a path the firm must discover itself.